Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: bioengineering – Page 10

AI turns printer into a partner in tissue engineering

In 3D bioprinting, researchers use living cells to create functional tissues and organs. Instead of printing with plastic, they print with living cells. This comes with great challenges. Cells are fragile and wouldn’t survive a regular 3D . That’s why Levato’s team developed a special bio-ink, a mix of living cells and nourishing gels that protect the cells during the printing process.

With the advancements in bio-inks, layer-by-layer 3D bioprinting became possible. But this method is still time-consuming and puts a lot of stress on the cells. Researchers from Utrecht came up with a solution: volumetric bioprinting.

Volumetric bioprinting is faster and gentler on cells. Using cell-friendly laser light, a 3D structure is created all at once. “To build a structure, we project a series of light patterns into a spinning tube filled with light-sensitive gel and cells,” Levato explains. “Where the light beams converge, the material solidifies. This creates a full 3D object in one go, without having to touch the cells.” To do this, it is crucial to know exactly where the cells are in the gel. GRACE now makes that possible.

Apertura Gene Therapy and Rett Syndrome Research Trust Collaborate to Pioneer Advanced Genetic Medicines for Rett Syndrome Using TfR1-Targeted AAV Capsid

NEW YORK and TRUMBULL, Conn., April 30, 2025 /PRNewswire/ — Apertura Gene Therapy, a biotechnology company focused on innovative gene therapy solutions, and the Rett Syndrome Research Trust (RSRT), an organization working to cure Rett Syndrome, today announced a collaboration to license Apertura’s human transferrin receptor 1 capsid (TfR1 CapX). This partnership aims to advance innovative genetic medicine approaches for the treatment of Rett Syndrome, a rare genetic neurological disorder caused by random mutations in the MECP2 gene on the X chromosome that primarily affect females, causing developmental regression and severe motor and language impairments.

Apertura’s TfR1 CapX is an intravenously delivered adeno-associated virus (AAV) capsid engineered to bind the transferrin receptor 1(TfR1), enabling efficient delivery of genetic medicines across the blood-brain barrier (BBB). TfR1 is a well-characterized BBB-crossing receptor, broadly and consistently expressed throughout life—even in the context of neurological disease—making it an attractive target for CNS delivery in disorders like Rett syndrome. Developed by Apertura’s academic founder, Dr. Ben Deverman, Director of Vector Engineering at the Broad Institute, TfR1 CapX has shown strong CNS selectivity in preclinical studies, achieving over 50% neuronal and 90% astrocyte transduction across multiple brain regions. Because Rett syndrome affects the brain diffusely, broader cellular transduction may correlate with greater symptomatic improvement.

DNA-based neural network learns from examples to solve problems

Neural networks are computing systems designed to mimic both the structure and function of the human brain. Caltech researchers have been developing a neural network made out of strands of DNA instead of electronic parts that carries out computation through chemical reactions rather than digital signals.

An important property of any neural network is the ability to learn by taking in information and retaining it for future decisions. Now, researchers in the laboratory of Lulu Qian, professor of bioengineering, have created a DNA-based neural network that can learn. The work represents a first step toward demonstrating more complex learning behaviors in .

A paper describing the research appears in the journal Nature on September 3. Kevin Cherry, Ph.D., is the study’s first author.

A light-programmable, dynamic ultrasound wavefront

The notion of a phased array was initially articulated by Nobel Prize recipient K. F. Braun. Phased arrays have subsequently evolved into a formidable mechanism for wave manipulation. This assertion holds particularly true in the realm of ultrasound, wherein arrays composed of ultrasound-generating transducers are employed in various applications, including therapeutic ultrasound, tissue engineering, and particle manipulation.

Importantly, these applications—contrary to those aimed at imaging—demand high-intensity ultrasound, which complicates the electrical driving requirements, as each channel necessitates its own independently operational pulse circuitry and amplifier. Consequently, the majority of phased array transducers (PATs) are constrained to several hundred elements, thereby restricting the capability to shape intricate ultrasound beams.

To date, there exists no scalable methodology for the powering and control of phased array transducers.

/* */